Innovative Research

Current Location:Innovative Research > Equity Investment

So far, CMS has made equity investment in several domestic and overseas innovative R&D companies in specific fields. Capitalizing on their professional teams with rich experiences in global pharmaceutical companies, as well as their advanced innovation technology platforms, the Group has deployed a number of innovative products.



China


Focus on developing new natural fully human monoclonal antibodies biopharmaceutics

Main Products

Fully Human Anti-SA Hlα Antibody
A natural fully human anti-SA antibody drug with Hlα neutralizing activity

Fully Human Anti-HCMV Antibody
A natural fully human antibody drug with HCMV neutralizing activity

Fully Human Anti-COVID-19 Antibody
A natural fully human anti-COVID-19 antibody effective against major current variants with low immunogenicity

US


Focus on developing a novel category of therapies for GI-related chronic diseases

Main Products

PLENITY®
U.S. FDA-cleared, safe and effective orally-administered weight management product made from naturally derived materials

UK


Focus on the R&D of medicines for oncology and immunotherapy

Main Products

MTX110
A new nano inclusion formulation used for the treatment of DIPG and can be delivered directly via convection enhanced delivery (CED), bypassing the blood-brain barrier

Switzerland


Focus on oral T-cell immunotherapies for patients suffering from cancer

Main Products

VXM01
Innovative oral T-cell immunoagonist for the treatment of multiple cancers such as recurrent glioblastoma

US


Focus on innovative treatment of central nervous system

Main Products

Diazepam Nasal Spray
An innovative drug aiming at acute repetitive seizures that is easy to use outside the medical setting and have a very rapid onset

US


Focus on innovative treatment of neurological wellness

Main Products

PoNS™
A groundbreaking and non-invasive portable neuromodulation stimulator with high cure rate, for treatment of balance disorders associated with brain-related disease

UK


Focus on developing innovative nanomedicines for difficult-to-treat skin and nail infections

Main Products

BB2603
Novel terbinafine-nano spray capable of effectively penetrating human toenail

France


Focus on innovative treatment in the therapy of acute thrombotic diseases

Main Products

ACT017
High-affinity anti-platelet humanized monoclonal antibody which does not increase the risk of bleeding

UK


Focus on new approach to the treatment of infectious disease

Main Products

XF-73
A rapid elimination of drug-resistant Staphylococcus aureus, a new type of nasal colonization antibiotic that is not susceptible to drug resistance